

Steve Sisolak
Governor

Richard Whitley, MS
Director



DEPARTMENT OF
HEALTH AND HUMAN SERVICES
DIVISION OF PUBLIC AND BEHAVIORAL HEALTH
Helping people. It's who we are and what we do.



Lisa Sherych
Administrator

Ihsan Azzam,
Ph.D., M.D.
Chief Medical Officer

Technical Bulletin

Date: July 2, 2021
Topic: ACIP Discussions on Myocarditis Post-COVID 19 Vaccination and Potential Need for COVID-19 Booster Doses
Contact: Karissa Loper, MPH, Bureau Chief, Bureau of Child, Family and Community Wellness
To: All Health Care Providers and Facilities

Myocarditis or Pericarditis following m-RNA vaccination:

On June 23, 2021, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) met to discuss the latest data on reports of mild cases of inflammation of the heart muscle and surrounding tissue called myocarditis and pericarditis following mRNA COVID-19 vaccination among younger people, and to discuss potential need for booster doses of COVID-19 vaccine. ACIP voting members discussed the risks and benefits of vaccinating adolescents with the risk of myocarditis. Voting members agreed that the benefits continue to outweigh the harms however this inflammatory condition needs to continue to be monitored with additional race/ethnicity data, and monitoring of myocarditis risk after dose 1 vs. dose 2 of mRNA vaccines.

Key considerations:

- myocarditis and pericarditis are extremely rare side effects.
- an exceedingly small number of younger people will experience it after vaccination.
- most cases are mild, and individuals recover often on their own or with minimal treatment.
- myocarditis and pericarditis are much more common *if you get COVID-19 infection*.
- the risks to the heart *from COVID-19 infection* can be more severe.

An Update on COVID-19 Vaccine Booster Doses:

By September, COVID-19 vaccine manufacturers will provide safety and immunogenicity data of booster doses. Populations considered for booster doses include adults 65+, immunocompromised individuals, healthcare personnel, and health care workers. In early fall, additional data should be available on COVID-19/variant epidemiology. The general ACIP consensus was that variants, safety, and special populations need to be closely monitored and studied further to make any booster dose recommendations. For more robust summary and links to the ACIP slide presentations please click [here](#).

Key considerations:

- There is currently not enough data to recommend booster doses.

For more information and resources on myocarditis and pericarditis after COVID-19 vaccination, visit CDC's website [here](#).

To read the statement following CDC ACIP Meeting from Nation's Leading Doctors, Nurses and Public Health Leaders on Benefits of Vaccination click [here](#).

Questions:

For updated guidance, please review the DPBH Technical Bulletin [website](#) and the Nevada Health Response [website](#) regularly. If you have other questions regarding the COVID-19 Vaccine Response, please email dpbh-covid19vax@health.nv.gov.



Lisa Sherych, Administrator
Division of Public and Behavioral Health



Ihsan Azzam, Ph.D., M.D.
Chief Medical Officer